**Gene therapy, other than onasemnogene abeparvovec, is used for pre-symptomatic and early symptomatic SMA patients less than one year of age, diagnosed by NBS, with SMN2 copy 1-3. Here, SMN2 is linked to proximal spinal muscular atrophy.